Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that its wholly owned subsidiary, Eucure has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
February 27, 2023
· 5 min read